John E.  Gallagher net worth and biography

John Gallagher Biography and Net Worth

Currently, John E. Gallagher occupies the position of Chief Financial Officer at Cue Health, Inc. and Treasurer for Accuri Cytometers, Inc.

In the past Mr. Gallagher held the position of Treasurer & CFO-Medical Segment at Becton, Dickinson & Co., Assistant Controller at General Electric Co. and VP-Financial Planning & Analysis at NBCUniversal Media LLC.

Mr. Gallagher received an undergraduate degree from Clemson University and an MBA from the University of Pittsburgh.

What is John E. Gallagher's net worth?

The estimated net worth of John E. Gallagher is at least $2.12 million as of February 27th, 2018. Mr. Gallagher owns 9,391 shares of Becton, Dickinson and Company stock worth more than $2,119,361 as of December 18th. This net worth approximation does not reflect any other assets that Mr. Gallagher may own. Learn More about John E. Gallagher's net worth.

How do I contact John E. Gallagher?

The corporate mailing address for Mr. Gallagher and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on John E. Gallagher's contact information.

Has John E. Gallagher been buying or selling shares of Becton, Dickinson and Company?

John E. Gallagher has not been actively trading shares of Becton, Dickinson and Company in the last ninety days. Most recently, John E. Gallagher sold 5,346 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $226.08, for a transaction totalling $1,208,623.68. Following the completion of the sale, the vice president now directly owns 9,391 shares of the company's stock, valued at $2,123,117.28. Learn More on John E. Gallagher's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 7 times. They sold a total of 14,018 shares worth more than $3,231,107.90. The most recent insider tranaction occured on December, 9th when EVP Roland Goette sold 638 shares worth more than $139,741.14. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 12/9/2024.

John E. Gallagher Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2018Sell5,346$226.08$1,208,623.689,391View SEC Filing Icon  
12/15/2016Sell1,793$168.82$302,694.262,796View SEC Filing Icon  
6/13/2016Sell1,931$169.87$328,018.976,758View SEC Filing Icon  
11/30/2015Sell1,600$150.70$241,120.003,393View SEC Filing Icon  
See Full Table

John E. Gallagher Buying and Selling Activity at Becton, Dickinson and Company

This chart shows John E Gallagher's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $225.68
Low: $223.41
High: $229.13

50 Day Range

MA: $230.57
Low: $220.02
High: $243.75

2 Week Range

Now: $225.68
Low: $218.75
High: $249.89

Volume

2,526,168 shs

Average Volume

1,470,588 shs

Market Capitalization

$65.25 billion

P/E Ratio

37.99

Dividend Yield

1.83%

Beta

0.41